FDAmanufacturing / CMC54% confidence
Other | Cancer Accelerated Approvals
Source: FDA
Why This Matters
Why this matters: sets a manufacturing / CMC precedent in the same sub-indication (lung cancer) as AstraZeneca.
Regulatory Analysis
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products and changes to dosing or formulation.
Supporting Context
- Therapeutic area
- Oncology · Lung Cancer
- Sub-indication
- Lung Cancer
Related signal: AstraZeneca Launches AI Study for Lung Cancer Risk Stratification